Andrew Hopkins, Exscientia CEO
Bristol Myers expands Celgene-era deal with Exscientia, taking its AI R&D engine to the next step
One day after taking a shot on an anti-TIGIT bispecific from Agenus, Bristol Myers Squibb is still in a dealmaking mood.
For Wednesday’s chaser …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
